<DOC>
	<DOCNO>NCT01982292</DOCNO>
	<brief_summary>The purpose study assess safety repeat dose serelaxin chronic heart failure .</brief_summary>
	<brief_title>Safety Repeat Doses IV Serelaxin Subjects With Chronic Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Key Body weight â‰¤ 160 kg . Subjects compensate CHF ( NYHA Class II III ) time screen prior document history chronic heart failure . NTproBNP &gt; 300 pg/ml ( accord central measurement ) visit 1 . Subjects treat appropriate guidelineindicated CHF standard care . Ability comply requirement , include ability receive least 48 hour infusion plus followup time require dosing visit . Key Current acute decompensated HF Any major solid organ transplant recipient plan anticipate organ transplant within 1 year . Documented history untreated ventricular arrhythmia syncopal episode , ventricular tachycardia , ventricular fibrillation without ICD ( implantable cardioverter defibrillator ) significant hemodynamic consequence within 3 month prior screen . Presence hemodynamically significant mitral /or aortic valve disease , except mitral regurgitation secondary leave ventricular dilatation : include significant leave ventricular outflow obstruction ( e.g. , obstructive hypertrophic cardiomyopathy , severe aortic stenosis ) Subjects severe renal impairment define prerandomization eGFR &lt; 30 ml/min/1.73m2 calculate use sMDRD equation and/or receive current plan dialysis ultrafiltration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Chronic Heart Failure , CHF , Heart Failure , HF , Immunogenicity , Anti-bodies , Hypersensitivity , Serelaxin , RELAX-REPEAT</keyword>
</DOC>